Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315507 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
A Phase 1 study, sponsored by PhaseBio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03315507 is a Phase 1 study that has completed, run by PhaseBio Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT03315507, a Phase 1 study, has completed, sponsored by PhaseBio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
PB1046-PT-CL-0005 is an open-label, dose-titration study to assess the safety, tolerability, and hemodynamic effects of individually dose-titrated PB1046 administered by weekly subcutaneous injection for 8 weeks in adult subjects with PAH who have a permanently implanted hemodynamic monitor in the distal pulmonary artery. The primary objectives of the study are to assess the overall safety, tolerability, and hemodynamic profile of a PB1046 across an individually titrated dose range.
Interventions
- DRUG PB1046 Subcutaneous Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2019-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315507
The ClinicalTrials.gov registry entry for NCT03315507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PhaseBio Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PB1046 Subcutaneous Injection is the first listed.
NCT03315507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03315507 about?
NCT03315507 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH". PB1046-PT-CL-0005 is an open-label, dose-titration study to assess the safety, tolerability, and hemodynamic effects of individually dose-titrated PB1046 administered by weekly subcutaneous injection for 8 weeks in adult subjects with PAH who have a permanently implanted hemodynamic monitor in the d...
What is the current status of trial NCT03315507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-10-20. Estimated completion is 2019-08-08.
What interventions are being tested in trial NCT03315507?
The interventions under investigation include: PB1046 Subcutaneous Injection (DRUG).
Who is sponsoring clinical trial NCT03315507?
This trial is sponsored by PhaseBio Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.